Radiotherapy (RT) after breast-conserving surgery (BCS) for breast cancer improves breast cancer mortality and decreases recurrence. 1 However, the benefit of adjuvant breast RT is partially offset by nonbreast morbidity caused by dose to normal structures, including the heart. 2 Various techniques and technologies are used to minimize the dose to surrounding normal structures including deep inspiration breath-hold, intensity-modulated radiation therapy, and proton beam therapy (PBT). 3 Adjuvant whole-breast RT can be delivered with photons or PBT. PBT offers unique dosimetric advantages, such as improved target and internal mammary nodal (IMN) coverage, 4,5 decreased lung dose, 6,7 and decreased heart dose. 6,7 However, PBT has some disadvantages including decreased patient access, 8 increased cost, 9 and higher rates of acute radiation dermatitis (RD). 10 We report a prospectively evaluated multi-institutional cohort of patients who received adjuvant whole-breast PBT after BCS for breast cancer. 2 | ME THODS The Proton Collaborative Group (PCG) REG001-09 trial is an IRBapproved, multi-institutional prospective registry of patients treated with PBT. Between 2012 and 2016, 82 patients underwent BCS followed by PBT to the whole breast at seven participating institutions.